Mutations and overexpression of the PSMB5 (β5) gene were observed in vitro in BTZ-adapted myeloma cell lines (8), but never in vivo in MM patients refractory to BTZ (9). This evidence concerns the gene PSMB5 and plasma cell myeloma.